All In Biotech

Drug Trial Radar · NCT02323659

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas

Last checked: Nov 20, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 1, 2014

Primary completion

Mar 2018

Study completion Mar 31, 2018

Sponsor

Lead sponsor
Polish Lymphoma Research GroupResearch network
Sponsor type
Research network
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.

Conditions

  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides

Interventions

  • MethotrexateDrug

    Methotrexate 20mg per dose, administered orally, once every week

  • Interferon Alfa-2bDrug

    Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate as measured by the modified Severity Weighted Assessment Tool (mSWAT scoring system)Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centrum Onkologii im. prof. F. Łukaszczyka

    Bydgoszcz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.